Ondansetron Use for Smoking Cessation

Abstract

Get full access to this article

View all access options for this article.

References

Cigarette smoking-attributable mortality and years of potential life lost–-United States, 1990. MMWR Morb Mortal Wkly Rep 1993;42:645-8.

Public health focus: effectiveness of smoking-control strategies–-United States. MMWR Morb Mortal Wkly Rep 1992;41:645-7, 653.

Cigarette smoking among adults–-United States, 1990. MMWR Morb Mortal Wkly Rep 1992;41:354-5, 361–2.

Nunn-Thompson

, Simon

. Pharmacotherapy for smoking cessation. Clin Pharm 1989;8:710-20.

Gora

. Nicotine transdermal systems. Ann Pharmacother 1993;27:742-50.

Package insert. Zofran (ondansetron hydrochloride). Research Triangle Park, NC: Glaxo, September 1994.

Carboni

, Acquas

, Frau

, Di

Chiara G.

Differential inhibitory effects of a 5-HT₃ antagonist on drug-induced stimulation of dopamine release. Eur J Pharmacol 1989;164:515-9.

Costall

, Jones

, Kelly

, Naylor

, Onaivi

, Tyers

. Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol Biochem Behav 1990;36:339-44.

Zacny

, Apfelbaum

, Lichtor

, Zaragoza

. Effects of 5-hydroxytryptamine-3 antagonist, ondansetron, on cigarette smoking, smoke exposure, and mood in humans. Pharmacol Biochem Behav 1993;44:387-91.